丙型肝炎病毒的抗病毒治疗：超越标准治疗。
Antiviral therapy for hepatitis C virus: beyond the standard of care.
机构信息
Rega Institute for Medical Research, KULeuven, Minderbroedersstraat 10, 3000 Leuven, Belgium.
出版信息
Viruses. 2010 Apr;2(4):826-866. doi: 10.3390/v2040826. Epub 2010 Mar 29.
Abstract
Hepatitis C virus (HCV) represents a major health burden, with an estimated 180 million chronically infected individuals worldwide. These patients are at increased risk of developing liver cirrhosis and hepatocellular carcinoma. Infection with HCV is the leading cause of liver transplantation in the Western world. Currently, the standard of care (SoC) consists of pegylated interferon alpha (pegIFN-α) and ribavirin (RBV). However this therapy has a limited efficacy and is associated with serious side effects. Therefore more tolerable, highly potent inhibitors of HCV replication are urgently needed. Both Specifically Targeted Antiviral Therapy for HCV (STAT-C) and inhibitors that are believed to interfere with the host-viral interaction are discussed.
摘要
丙型肝炎病毒（HCV）是一个主要的健康负担，全球估计有 1.8 亿慢性感染者。这些患者发生肝硬化和肝细胞癌的风险增加。HCV 感染是西方世界进行肝移植的主要原因。目前，标准治疗（SoC）包括聚乙二醇干扰素α（pegIFN-α）和利巴韦林（RBV）。然而，这种治疗方法疗效有限，并且与严重的副作用相关。因此，迫切需要更耐受、高效的 HCV 复制抑制剂。本文讨论了丙型肝炎的特异性靶向抗病毒治疗（STAT-C）和那些被认为干扰宿主-病毒相互作用的抑制剂。
相似文献
1
Antiviral therapy for hepatitis C virus: beyond the standard of care.
Viruses. 2010 Apr;2(4):826-866. doi: 10.3390/v2040826. Epub 2010 Mar 29.
2
Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 13;3(3):CD011644. doi: 10.1002/14651858.CD011644.pub2.
3
Treatment of chronic hepatitis C in Asia: when East meets West.
J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x.
4
Antiviral treatment of hepatitis C virus infection and factors affecting efficacy.
World J Gastroenterol. 2013 Dec 21;19(47):8963-73. doi: 10.3748/wjg.v19.i47.8963.
5
A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
J Infect Chemother. 2014 May;20(5):320-4. doi: 10.1016/j.jiac.2013.11.006. Epub 2014 Jan 27.
6
NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements. 2002;19(3):1-46.
7
Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.
Virol J. 2005 Dec 2;2:89. doi: 10.1186/1743-422X-2-89.
8
New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x.
9
Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
AIDS. 2015 Mar 13;29(5):571-81. doi: 10.1097/QAD.0000000000000579.
10
Effects of Pegylated Interferon Alpha and Ribavirin (pegIFN-α/RBV) Therapeutic Approach on Regulatory T Cells in HCV-Monoinfected and HCV/HIV-Coinfected Patients.
Viruses. 2021 Jul 25;13(8):1448. doi: 10.3390/v13081448.
引用本文的文献
1
Artemisinin analogues as potent inhibitors of in vitro hepatitis C virus replication.
PLoS One. 2013 Dec 11;8(12):e81783. doi: 10.1371/journal.pone.0081783. eCollection 2013.
2
Inhibitors for the hepatitis C virus RNA polymerase explored by SAR with advanced machine learning methods.
Bioorg Med Chem. 2013 Jun 1;21(11):3127-37. doi: 10.1016/j.bmc.2013.03.032. Epub 2013 Mar 29.
3
Intervention strategies for emerging viruses: use of antivirals.
Curr Opin Virol. 2013 Apr;3(2):217-24. doi: 10.1016/j.coviro.2013.03.001. Epub 2013 Apr 4.
4
Hepatitis C virus NS5B and host cyclophilin A share a common binding site on NS5A.
J Biol Chem. 2012 Dec 28;287(53):44249-60. doi: 10.1074/jbc.M112.392209. Epub 2012 Nov 14.
5
The burden of untreated hepatitis C virus infection: a US patients' perspective.
Dig Dis Sci. 2012 Nov;57(11):2995-3003. doi: 10.1007/s10620-012-2233-1. Epub 2012 Jun 5.
6
New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.
J Zhejiang Univ Sci B. 2012 Jan;13(1):56-82. doi: 10.1631/jzus.B1100120.
7
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
Nat Biotechnol. 2011 Nov 8;29(11):993-1003. doi: 10.1038/nbt.2020.
8
Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.
Viruses. 2010 Oct;2(10):2169-2195. doi: 10.3390/v2102169. Epub 2010 Sep 28.
9
Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication.
Antimicrob Agents Chemother. 2011 Sep;55(9):4103-13. doi: 10.1128/AAC.00294-11. Epub 2011 Jun 27.
10
Inhibition of hepatitis C virus replication by semi-synthetic derivatives of glycopeptide antibiotics.
J Antimicrob Chemother. 2011 Jun;66(6):1287-94. doi: 10.1093/jac/dkr104. Epub 2011 Mar 24.
本文引用的文献
1
Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C.
J Viral Hepat. 2011 May;18(5):331-7. doi: 10.1111/j.1365-2893.2010.01310.x.
2
A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues.
Antiviral Res. 2010 May;86(2):144-53. doi: 10.1016/j.antiviral.2010.02.312. Epub 2010 Feb 13.
3
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Gastroenterology. 2010 Mar;138(3):1112-22. doi: 10.1053/j.gastro.2009.11.053. Epub 2009 Dec 4.
4
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro.
Antimicrob Agents Chemother. 2010 Feb;54(2):660-72. doi: 10.1128/AAC.00660-09. Epub 2009 Nov 23.
5
Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Gastroenterology. 2010 Mar;138(3):913-21. doi: 10.1053/j.gastro.2009.10.033. Epub 2009 Oct 21.
6
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.
7
MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease.
Antimicrob Agents Chemother. 2010 Jan;54(1):305-11. doi: 10.1128/AAC.00677-09. Epub 2009 Oct 19.
8
Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor.
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2054-60. doi: 10.1161/ATVBAHA.109.191320. Epub 2009 Oct 8.
9
Identification of hepatitis C virus NS5A inhibitors.
J Virol. 2010 Jan;84(1):482-91. doi: 10.1128/JVI.01360-09.
10
The hepatitis C virus and its hepatic environment: a toxic but finely tuned partnership.
Biochem J. 2009 Oct 12;423(3):303-14. doi: 10.1042/BJ20091000.
Zotero 插件